{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasmapheresis",
    "query": {
      "intervention": "Plasmapheresis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 102,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasmapheresis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T20:01:07.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07087860",
      "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma",
        "Refractory Bladder Urothelial Carcinoma",
        "Refractory Renal Pelvis and Ureter Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v7",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Central Venous Cannula Insertion",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Antibody-Drug Conjugate Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-08-01",
      "completion_date": "2028-08-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07087860"
    },
    {
      "nct_id": "NCT04445220",
      "title": "A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Kidney Injury",
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "SBI-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sentien Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-11-19",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 2,
      "location_summary": "Albuquerque, New Mexico • Charleston, South Carolina",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445220"
    },
    {
      "nct_id": "NCT03702920",
      "title": "Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute-On-Chronic Liver Failure"
      ],
      "interventions": [
        {
          "name": "SMT + PE-A 5%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Medical Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 274,
      "start_date": "2019-06-17",
      "completion_date": "2025-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 10,
      "location_summary": "Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03702920"
    },
    {
      "nct_id": "NCT06597656",
      "title": "A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "MALE",
        "summary": "4 Years to 8 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2024-09-18",
      "completion_date": "2025-08-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06597656"
    },
    {
      "nct_id": "NCT03887741",
      "title": "Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Plasmapheresis",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasma infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2021-09-15",
      "completion_date": "2024-02-16",
      "has_results": false,
      "last_update_posted_date": "2024-12-31",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887741"
    },
    {
      "nct_id": "NCT04320823",
      "title": "IMPACT (Improving Plasma Collection) Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Apheresis Related Hypotension"
      ],
      "interventions": [
        {
          "name": "Updated Plasma Collection Feature",
          "type": "DEVICE"
        },
        {
          "name": "Current Plasma Collection Approach",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Haemonetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 3443,
      "start_date": "2020-01-06",
      "completion_date": "2020-04-27",
      "has_results": true,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 3,
      "location_summary": "Wichita, Kansas • Charlotte, North Carolina • Spokane, Washington",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320823"
    },
    {
      "nct_id": "NCT02522572",
      "title": "Quantitating the Impact of Plerixafor",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transplants and Implants"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "plasmapheresis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "E. Steve Woodle",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-08",
      "completion_date": "2020-10",
      "has_results": false,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02522572"
    },
    {
      "nct_id": "NCT06122935",
      "title": "Evaluation of the Aurora Xi New Nomogram Software 2.0",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Apheresis Related Hypotension"
      ],
      "interventions": [
        {
          "name": "Aurora Xi New Nomogram Software 2.0",
          "type": "DEVICE"
        },
        {
          "name": "Aurora Xi Currently Approved Software 1.3",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Fenwal, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6735,
      "start_date": "2023-11-27",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 3,
      "location_summary": "Lakeland, Florida • West Des Moines, Iowa • American Fork, Utah",
      "locations": [
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "American Fork",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06122935"
    },
    {
      "nct_id": "NCT02553317",
      "title": "Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2015-11",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553317"
    },
    {
      "nct_id": "NCT01777412",
      "title": "Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2013-06",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2015-08-21",
      "last_synced_at": "2026-09-01T20:01:07.261Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777412"
    }
  ]
}